英文名称 |
中文名称 |
CAS |
lubiprostone
|
鲁比前列酮 |
333963-40-9 |
Trifluridine
|
三氟胸苷 |
70-00-8 |
Choline Fenofibrate
|
非诺贝特胆碱 |
856676-23-8 |
Levalbuterol hydrochloride
|
盐酸左旋沙丁胺醇 |
50293-90-8 |
SalbutaMon Hydrochloride
|
盐酸沙丁胺醇 |
41489-89-8 |
Salbutamol
|
左旋沙丁胺醇 |
34391-04-3 |
Tafluprost
|
他氟前列素 |
209860-87-7 |
Edoxaban tosylate
|
艾多沙班 |
480449-71-6 |
evocalcet
|
伊万卡赛 |
870964-67-3 |
tert-Butyl [(1R,2S,5S)-2-amino-5-[(dimethylamino)carbonyl]cyclohexyl]carbamate oxalate
|
艾多沙班中间体7 |
1210348-34-7 |
Cyclohexanecarboxamide, 4-bromo-3-hydroxy-N,N-dimethyl-, (1S,3S,4S)-
|
艾多沙班中间体2 |
1629245-79-9 |
ZVPVPYWMFMUFEZ-UHFFFAOYSA-N
|
雷芬那辛杂质 |
909800-36-8 |
(1S,4S,5S)-4-Bromo-6-oxabicyclo[3.2.1]octan-7-one
|
艾多沙班中间体1 |
139893-81-5 |
(1S,3R,4R)-3-amino-4-hydroxy-N,N-dimethylcyclohexanecarboxamide
|
艾多沙班中间体4 |
929693-36-7 |
Cyclohexanecarboxamide, 3-amino-4-hydroxy-N,N-dimethyl-, hydrobromide (1:1), (1S,3R,4R)-
|
艾多沙班中间体4(HBr) |
2964483-51-8 |
Carbamic acid, N-[[[(1R,2R,5S)-5-[(dimethylamino)carbonyl]-2-hydroxycyclohexyl]amino]sulfonyl]-, 1,1-dimethylethyl ester
|
艾多沙班中间体5 |
1629245-68-6 |
(1R,2R,4S)-2-[(tert-butoxycarbonyl)aMino]-4-[(diMethylaMino)carbonyl]cyclohexyl Methanesulfonate
|
艾多沙班中间体9 |
929693-31-2 |
(1S,3S,6R)-N,N-dimethyl-7-oxabicyclo[4.1.0]heptane-3-carboxamide
|
艾多沙班中间体3 |
929693-35-6 |
Edoxaban Impurity 16
|
艾多沙班中间体10 |
480450-69-9 |
carbamic acid, n-[(1r,2r,5s)-5-[(dimethylamino)carbonyl]-2-hydroxycyclohexyl]-, 1,1-dimethylethyl ester
|
艾多沙班中间体8 |
929693-30-1 |
Disalicylimide
|
地拉罗司杂质Int1-Imp1 |
1972-71-0 |
NA
|
地西他滨杂质Imp-F |
|
Deferasirox Isopropyl Ester
|
地拉罗司杂质Imp9 |
1266741-29-0 |
NA
|
地拉罗司杂质Imp14 |
|
4H-1,3-Benzoxazin-4-one, 2-(5-chloro-2-hydroxyphenyl)-
|
地拉罗司杂质Int1-Imp5 |
24798-50-3 |
NA
|
地西他滨杂质Imp-B |
|
Deferasirox Methyl Ester
|
地拉罗司杂质Imp8 |
1266741-05-2 |
Platinum(2+), diamminediaqua-, (SP-4-2)-, dinitrate
|
奈达铂杂质Imp-C |
52241-26-6 |
azanide: dihydroxy-oxo-azanium: platinum(+4) cation: dihydroxide
|
奈达铂杂质Imp-E |
62048-58-2 |
4H-1,3-Benzoxazin-4-one, 6-chloro-2-(2-hydroxyphenyl)-
|
地拉罗司杂质Int1-Imp5 |
26276-85-7 |
Platinum, diamminechloro(hydroxyacetato-O1)-, (SP-4-3)- (9CI)
|
奈达铂杂质Imp-G |
157176-10-8 |
1,3,5-Triazin-2(1H)-one, 4-amino-1-(2-deoxy-α-D-erythro-pentofuranosyl)-3,6-dihydro-
|
地西他滨Imp-G |
114522-17-7 |
Deferasirox
|
地拉罗司 |
201530-41-8 |
trans-Dichlorodiamineplatinum(II)
|
奈达铂杂质Imp-F |
14913-33-8 |
Deferasirox Ethyl Ester
|
地拉罗司杂质Imp4 |
201530-79-2 |
Benzoic acid, 4-[5-(5-chloro-2-hydroxyphenyl)-3-(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl]-
|
地拉罗司杂质Imp16 |
1620154-59-7 |
Esomeprazole
|
艾司奥美拉唑 |
119141-88-7 |
Ilaprazole
|
艾普拉唑 |
172152-36-2 |
PeMetrexed EP IMpurity A
|
培美曲塞二钠杂质ImpA |
869791-42-4 |
2-Pyridinecarboxylic acid, 1,4-dihydro-5-methyl-4-oxo-1-[6-(1H-pyrrol-1-yl)-1H-benzimidazol-2-yl]-
|
艾普拉唑杂质 |
1508282-87-8 |
Pemetrexed Disodium
|
培美曲塞二钠 |
150399-23-8 |
Palonosetron Hydrochloride
|
盐酸帕诺司琼 |
135729-62-3 |
PeMetrexed EP IMpurity E
|
培美曲塞二钠异构体 |
182009-04-7 |
PALONOSETRON HCL
|
盐酸帕诺司琼RR 异构体 |
135729-75-8 |
PeMetrexed EP IMpurity D
|
培美曲塞二钠杂质ImpD |
144051-68-3 |
PeMetrexed EP IMpurity B
|
培美曲塞二钠杂质ImpB |
1802552-04-0 |
PeMetrexed EP IMpurity C
|
培美曲塞二钠杂质ImpC |
1802552-16-4 |
EsoMeprazole related substance H431/41
|
艾司奥美拉唑杂质 |
1227380-90-6 |
Deferasirox Impurity 8
|
地拉罗司杂质Imp6 |
201530-78-1 |
Methyl 4-hydroxy-7-phenoxyisoquinoline-3-carboxylate
|
罗沙司他中间体 |
1455091-10-7 |
Riociguat
|
利奥西呱 |
625115-55-1 |
tert-butyl (1R,2S,5S)-2-aMino-5-(diMethylcarbaMoyl)cyclohexylcarbaMate
|
艾多沙班中间体6 |
365998-36-3 |
Cabozantinib impurity 26
|
卡博替尼杂质 |
2840522-80-5 |
Platinum (II), diammineoxalato-, cis-
|
奈达铂杂质Imp-A |
41349-15-9 |
Platinum, diamminedihydroxy[2-(hydroxy-κO)acetato(2-)-κO]-, (OC-6-44)-
|
奈达铂杂质Imp-D |
103436-60-8 |
NA
|
地西他滨杂质Imp-L |
|
1,1-Cyclopropanedicarboxamide, N,N'-bis[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-
|
卡博替尼杂质 |
2439164-91-5 |
NA
|
地拉罗司杂质Imp7 |
|
NA
|
地西他滨杂质Imp-A |
|